NAS:RVPHW (USA)
Â
Warrants (25/12/2025)
$
0.0030
-0.00060 (-16.67%)
03:53 PM EST
Business Description
Reviva Pharmaceuticals Holdings Inc
NAICS : 325412
SIC : 2834
Share Class Description:
RVPHW: Warrants (25/12/2025)Total Employee Number:
14Description
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 138.13 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 42.6 | |||||
3-Year EPS without NRI Growth Rate | 42.4 | |||||
3-Year FCF Growth Rate | 29.6 | |||||
3-Year Book Growth Rate | -43.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 44.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.56 | |||||
Quick Ratio | 3.56 | |||||
Cash Ratio | 3.35 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -79.1 | |||||
Shareholder Yield % | -288 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -143.47 | |||||
ROA % | -75.2 | |||||
ROIC % | -1098.53 | |||||
3-Year ROIIC % | 699.39 | |||||
ROCE % | -143.05 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.46 | |||||
EV-to-EBIT | 0.98 | |||||
EV-to-EBITDA | 0.98 | |||||
EV-to-FCF | 0.74 | |||||
Earnings Yield (Greenblatt) % | 102.04 | |||||
FCF Yield % | -247.86 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RVPHW
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Reviva Pharmaceuticals Holdings Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | - | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | - | ||
| 20-Day SMA ($) | - | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 0 - 3 | ||
| Shares Outstanding (Mil) |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Reviva Pharmaceuticals Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Reviva Pharmaceuticals Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-18 11:00 | In 99 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 63 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | -- | ||
| Life Sciences Virtual Investor Forum | 2026-06-24 13:30 | -- | ||
| A.G.P. Annual Healthcare Company Showcase | 2026-05-20 14:40 | -- | ||
| First quarter earnings results for 2026 | 2026-05-13 | -- | ||
| Reviva Pharmaceuticals (RVPH) Fireside Chat: | 2026-04-27 11:00 | -- | ||
| Annual report for 2025 | 2026-03-30 | -- | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | -- | ||
| General meeting for 2025 | 2025-12-18 11:00 | -- |
Show
Entries
Reviva Pharmaceuticals Holdings Inc Frequently Asked Questions
What is Reviva Pharmaceuticals Holdings Inc(RVPHW)'s stock price today?
The current price of RVPHW is $0.00. The 52 week high of RVPHW is $3.00 and 52 week low is $0.00.
When is next earnings date of Reviva Pharmaceuticals Holdings Inc(RVPHW)?
The next earnings date of Reviva Pharmaceuticals Holdings Inc(RVPHW) is 2026-11-13 Est..
Does Reviva Pharmaceuticals Holdings Inc(RVPHW) pay dividends? If so, how much?
Reviva Pharmaceuticals Holdings Inc(RVPHW) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers